You're contacting media contact of this press release

Title: Salience Clinical Introduces S2G Framework Pairing AI Screening with Physician-Executive GestaltSubmissions

PRINCETON, N.J., United States, 15th Sep 2026 -  Salience Clinical, LLC, a clinical development and regulatory advisory consultancy, today announced the launch of the Salience Signal-to-Gestalt (S2G) Framework. The methodology addresses a major industry pain point: clinical programs produce massive amounts of digital biomarkers, sensor data, and real-world evidence (RWE) that create an unmanageable flood of false signals using conventional statistical tools, while opaque machine learning algorithms fail to provide regulators the biological plausibility and audit trail they demand.This problem is addressed by the S2G Framework, which employs a four-tier, Human-in-the-Loop (HITL) pipeline connecting computational screening directly to senior physician judgment:Tier 1 – Multi-Source Ingestion & Harmonization: Pulls together high-entropy datasets including clinical trial safety databases, EHRs, continuous sensor streams, and biomarker panels normalizing data syntax and removing background noise.Tier 2 – Explainable AI & Signal Detection: Uses auditable algorithms aligned with FDA Good Machine Learning Practice (GMLP), cross-center AI credibility assessment frameworks, and lifecycle management standards (including Predetermined Change Control Plans [PCCP] when applicable for digital endpoints and SaMD) to detect real safety clusters and efficacy trends with end-to-end data provenance. Tier 3 – Mechanistic & Pharmacodynamic Triangulation: Cross-references statistical flags with target pharmacology, receptor binding profiles, and biological pathways to identify true pharmacodynamic effects vs. computational artifacts. Tier 4 – The Salience Gestalt Synthesis: The output filters transition directly to Denis Katz, M.D., Founder and Medical Director of S...

This press release is issued by King Newswire